INCYTE CORPORATION (INCY) Spending and interest coverage
- R&D / revenue · 12 months: Value 39.71%; Formula and calculation Research and development expense / revenue. Period ending 2026-03-31..
- Stock-based compensation / revenue · 12 months: Value 4.71%; Formula and calculation Share-based compensation / revenue. Period ending 2026-03-31..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 39.71% | Research and development expense / revenue. Period ending 2026-03-31. $2.13B ÷ $5.36B × 100 ≈ 39.71% |
| Stock-based compensation / revenue · 12 months | 4.71% | Share-based compensation / revenue. Period ending 2026-03-31. $252.49M ÷ $5.36B × 100 ≈ 4.71% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 2.13B USD | Research and Development Expense |
| Revenue | 5.36B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 252.49M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 1.61B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | $2.13B | $5.36B | $252.49M | $1.61B | (m) | 39.71% | 4.71% | (m) | (m) |
| 2025-12-31 | $2.05B | $5.14B | $249.35M | $1.51B | (m) | 39.88% | 4.85% | (m) | (m) |
| 2025-09-30 | $1.90B | $4.81B | $258.91M | $1.48B | (m) | 39.58% | 5.38% | (m) | (m) |
| 2025-06-30 | $1.97B | $4.58B | $275.23M | $1.18B | (m) | 43.00% | 6.00% | (m) | (m) |
| 2025-03-31 | $2.61B | $4.41B | $267.26M | $174.64M | (m) | 59.25% | 6.06% | (m) | (m) |
| 2024-12-31 | $2.61B | $4.24B | $266.06M | $61.37M | (m) | 61.46% | 6.27% | (m) | (m) |
| 2024-09-30 | $2.59B | $4.08B | $254.33M | $-52.88M | (m) | 63.43% | 6.24% | (m) | (m) |
| 2024-06-30 | $2.39B | $3.86B | $224.41M | $15.74M | (m) | 61.91% | 5.82% | (m) | (m) |
| 2024-03-31 | $1.65B | $3.77B | $222.29M | $687.65M | $2.51M | 43.80% | 5.90% | 273.75× | Reported |
| 2023-12-31 | $1.63B | $3.70B | $215.89M | $620.52M | $2.55M | 44.04% | 5.84% | 243.25× | Reported |
| 2023-09-30 | $1.68B | $3.61B | $208.58M | $503.35M | $2.41M | 46.67% | 5.78% | 208.51× | Reported |
| 2023-06-30 | $1.69B | $3.51B | $205.98M | $427.02M | $2.43M | 48.18% | 5.86% | 175.58× | Reported |
| 2023-03-31 | $1.64B | $3.47B | $197.96M | $487.67M | $2.46M | 47.24% | 5.70% | 198.64× | Reported |
| 2022-12-31 | $1.59B | $3.39B | $188.42M | $579.44M | $2.67M | 46.72% | 5.55% | 217.34× | Reported |
| 2022-09-30 | $1.56B | $3.33B | $183.96M | $620.08M | $2.75M | 46.76% | 5.52% | 225.40× | Reported |
| 2022-06-30 | $1.51B | $3.32B | $181.25M | $717.12M | $2.55M | 45.43% | 5.46% | 281.33× | Reported |
| 2022-03-31 | $1.50B | $3.11B | $179.49M | $603.52M | $2.23M | 48.31% | 5.76% | 270.76× | Reported |
| 2021-12-31 | $1.46B | $2.99B | $183.01M | $585.78M | $1.91M | 48.83% | 6.13% | 307.01× | Reported |
| 2021-09-30 | $1.39B | $2.91B | $180.04M | $639.27M | $1.58M | 47.76% | 6.18% | 403.58× | Reported |
| 2021-06-30 | $1.49B | $2.72B | $181.15M | $409.19M | $1.69M | 54.93% | 6.66% | 242.27× | Reported |
| 2021-03-31 | $1.44B | $2.70B | $182.72M | $499.13M | $1.93M | 53.19% | 6.76% | 258.48× | Reported |
| 2020-12-31 | $2.22B | $2.67B | $177.88M | $-263.68M | $2.17M | 83.10% | 6.67% | -121.29× | Reported |
| 2020-09-30 | $2.12B | $2.46B | $174.64M | $-332.90M | $2.35M | 86.42% | 7.11% | -141.48× | Reported |
| 2020-06-30 | $1.97B | $2.39B | $174.20M | $-203.91M | $2.41M | 82.35% | 7.30% | -84.75× | Reported |
| 2020-03-31 | $1.97B | $2.23B | $168.51M | $-336.07M | $2.12M | 88.31% | 7.56% | -158.37× | Reported |
| 2019-12-31 | $1.15B | $2.16B | $166.59M | $402.01M | $1.85M | 53.46% | 7.72% | 216.71× | Reported |
| 2019-09-30 | $1.15B | $2.11B | $161.89M | $388.97M | $1.60M | 54.35% | 7.68% | 242.65× | Reported |
| 2019-06-30 | $1.16B | $2.01B | $156.53M | $285.78M | $1.41M | 57.66% | 7.80% | 202.53× | Reported |
| 2019-03-31 | $1.17B | $2.00B | $152.52M | $270.40M | $1.49M | 58.34% | 7.64% | 181.11× | Reported |
| 2018-12-31 | $1.20B | $1.88B | $148.15M | $129.22M | $1.54M | 63.66% | 7.87% | 83.75× | Reported |
| 2018-09-30 | $1.34B | $1.80B | $144.60M | $-85.52M | $1.56M | 74.59% | 8.04% | -54.78× | Reported |
| 2018-06-30 | $1.32B | $1.73B | $141.53M | $-101.62M | $1.36M | 76.20% | 8.18% | -74.72× | Reported |
| 2018-03-31 | $1.22B | $1.53B | $138.67M | $-177.60M | $1.35M | 79.61% | 9.04% | -131.94× | Reported |
| 2017-12-31 | $1.33B | $1.54B | $133.06M | $-243.73M | $6.90M | 86.34% | 8.66% | -35.32× | Reported |
| 2017-09-30 | $1.04B | $1.42B | $126.89M | $-69.07M | $16.00M | 73.38% | 8.94% | -4.32× | Reported |
| 2017-06-30 | $914.58M | $1.31B | $118.49M | $-61.73M | $25.27M | 70.00% | 9.07% | -2.44× | Reported |
| 2017-03-31 | $833.01M | $1.23B | $106.05M | $-24.34M | $34.55M | 67.93% | 8.65% | -0.70× | Reported |
| 2016-12-31 | $581.86M | $1.11B | $96.20M | $145.00M | $38.74M | 52.62% | 8.70% | 3.74× | Reported |
| 2016-09-30 | $536.91M | $1.02B | $85.69M | $168.00M | $39.49M | 52.48% | 8.38% | 4.25× | Reported |
| 2016-06-30 | $525.80M | $941.24M | $76.79M | $145.60M | $41.22M | 55.86% | 8.16% | 3.53× | Reported |
| 2016-03-31 | $517.97M | $857.94M | $73.08M | $93.63M | $43.05M | 60.37% | 8.52% | 2.17× | Reported |
| 2015-12-31 | $479.51M | $753.75M | $69.87M | $50.65M | $45.60M | 63.62% | 9.27% | 1.11× | Reported |
| 2015-09-30 | $461.60M | $633.84M | $68.68M | $-40.05M | $47.91M | 72.83% | 10.84% | -0.84× | Reported |
| 2015-06-30 | $418.06M | $644.38M | $66.48M | $29.99M | $48.16M | 64.88% | 10.32% | 0.62× | Reported |
| 2015-03-31 | $390.30M | $580.98M | $64.37M | $11.20M | $48.07M | 67.18% | 11.08% | 0.23× | Reported |
| 2014-12-31 | $347.52M | $511.50M | $62.16M | $-4.80M | $46.83M | 67.94% | 12.15% | -0.10× | Reported |
| 2014-09-30 | $323.82M | $484.59M | $56.07M | $4.68M | $43.24M | 66.82% | 11.57% | 0.11× | Reported |
| 2014-06-30 | $306.99M | $371.57M | $50.09M | $-78.45M | $39.48M | 82.62% | 13.48% | -1.99× | Reported |
| 2014-03-31 | $283.26M | $373.66M | $44.55M | $-34.94M | $38.37M | 75.81% | 11.92% | -0.91× | Reported |
| 2013-12-31 | $260.44M | $354.95M | $38.40M | $-16.10M | $38.65M | 73.37% | 10.82% | -0.42× | Reported |
| 2013-09-30 | $245.18M | $371.72M | $37.64M | $30.29M | $41.48M | 65.96% | 10.13% | 0.73× | Reported |
| 2013-06-30 | $223.56M | $347.09M | $37.78M | $33.34M | $45.36M | 64.41% | 10.88% | 0.73× | Reported |
| 2013-03-31 | $214.19M | $331.96M | $37.76M | $31.24M | $46.50M | 64.52% | 11.37% | 0.67× | Reported |
| 2012-12-31 | $210.39M | $297.06M | $38.49M | $1.15M | $46.06M | 70.82% | 12.96% | 0.02× | Reported |
| 2012-09-30 | $202.50M | $212.10M | $36.87M | $-73.25M | $45.45M | 95.47% | 17.38% | -1.61× | Reported |
| 2012-06-30 | $196.93M | $168.39M | $34.69M | $-105.21M | $44.89M | 116.94% | 20.60% | -2.34× | Reported |
| 2012-03-31 | $191.38M | $98.66M | $31.97M | $-161.55M | $44.35M | 193.98% | 32.40% | -3.64× | Reported |
| 2011-12-31 | $178.71M | $94.45M | $28.98M | $-143.18M | $43.82M | 189.20% | 30.68% | -3.27× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $123.88M | $169.88M | $14.86M | $14.05M | $43.32M | 72.92% | 8.75% | 0.32× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $119.44M | $9.27M | $9.98M | $-139.77M | $32.13M | 1289.17% | 107.72% | -4.35× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |